Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
11.91
-0.25 (-2.06%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Company Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Aug 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 161 |
| CEO | Mark Lappe |
Contact Details
Address: 11025 North Torrey Pines Road, Suite 140 La Jolla, California 92037 United States | |
| Phone | 858 795 4220 |
| Website | inhibrx.com |
Stock Details
| Ticker Symbol | INBX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001739614 |
| CUSIP Number | 45720L107 |
| ISIN Number | US45720L1070 |
| Employer ID | 82-4257312 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark Paul Lappe | Founder, Chief Executive Officer and Chairman |
| David Matly M.B.A. | President and Chief Commercial and Business Development Officer |
| Kelly Devine Deck B.S., CPA, M.S. | Executive Vice President, Chief Financial Officer and Treasurer |
| Bonne Adams M.B.A. | Vice President of Operations |
| Dr. Ashraf Amanullah Ph.D. | Executive Vice President and Chief Technical Operations Officer |
| Dr. Carlos Bais Ph.D. | Chief Scientific Officer |
| Leah Pollema J.D. | Vice President and General Counsel |
| Dr. Josep Garcia Ph.D. | Executive Vice President and Chief Clinical Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 10, 2024 | 15-12G | Securities registration termination |
| Jun 3, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 31, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| May 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 30, 2024 | POSASR | Filing |
| May 30, 2024 | 8-K | Current Report |